from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. An experimental antithrombotic.


Sorry, no etymologies found.


  • One group received treatment with semuloparin, which is a type of heparin, while they were undergoing chemotherapy.

    Yahoo! News: Business - Opinion

  • WEDNESDAY, Feb. 15 HealthDay News -- A new blood-thinning medication called semuloparin reduces the risk of blood clots in people undergoing certain cancer treatments, new research shows.

    Yahoo! News: Business - Opinion

  • An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in - latest science and technology news stories

  • Throughout 2011, further newsflow from R&D is expected with Phase III studies expected to be completed/reported for five compounds currently in development lixisenatide, teriflunomide, aflibercept, ombrabulin, and semuloparin.

  • The incidence of any type of excessive bleeding was 2.8 percent for the semuloparin group and 2.0 percent in those on placebo.

    Yahoo! News: Business - Opinion

  • Blood clots occurred in just 1.2 percent of those taking semuloparin compared to 3.4 percent of those on the placebo, according to the study.

    Yahoo! News: Business - Opinion

  • Major bleeding occurred in 1.2 percent of those on semuloparin and 1.1 percent of those on placebo.

    Yahoo! News: Business - Opinion

  • The follow-up analysis of three recently completed international clinical studies on short-term venous thromboembolism (VTE) protective medicine in patients undergoing major orthopedic surgery demonstrated that the ultra-low-molecular-weight heparin semuloparin reduced the incidence of VTE and all-cause death by 25 per cent compared to the commonly used therapy drug enoxaparin (a low-molecular-weight heparin). - latest science and technology news stories

  • The objective of the three studies was to assess once-daily preventative treatment with semuloparin (20 mg) compared to enoxaparin (40 mg daily in hip, and 30 mg twice-daily for knee) for seven to 10 days. - latest science and technology news stories

  • The SAVE program is supported by sanofi-aventis, producer of semuloparin. - latest science and technology news stories


Log in or sign up to get involved in the conversation. It's quick and easy.